Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The award recognizes powerful science–industry collaborations for social good
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subscribe To Our Newsletter & Stay Updated
